QuidelOrtho COO gets RSUs, options and net shares
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported multiple equity compensation transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported multiple equity compensation transactions. On January 30, 2026, he received 36,152 restricted stock units and 36,150 non-qualified stock options with a $27.17 exercise price, vesting in tranches from 2027 to 2029. On January 31, 2026, several blocks of restricted stock units converted into common stock, increasing his direct holdings, while the company withheld shares at $27.17 per share to cover tax obligations. After these transactions, he directly owned 19,174 shares of common stock, plus the newly granted RSUs and options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,127 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 847 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units (Converted) | 2,009 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units (Premium ) | 634 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,127 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 421 | $27.17 | $11K |
| Grant/Award | Common Stock | 847 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 304 | $27.17 | $8K |
| Grant/Award | Common Stock | 2,009 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 674 | $27.17 | $18K |
| Grant/Award | Common Stock | 634 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 228 | $27.17 | $6K |
| Grant/Award | Restricted Stock Units | 36,152 | $0.00 | $0.00 |
| Grant/Award | Non-Qualified Stock Options | 36,150 | $0.00 | $0.00 |
Footnotes (8)
- F1. Reflects release of restricted stock units that were previously reported on a Form 3 or Form 4.
- F2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
- F3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
- F4. 12,050 shares will vest on January 30, 2027; the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029.
- F5. 36,150 shares will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029.
- F6. 2,254 shares vested in equal installments on January 31, 2025 and January 31, 2026.
- F7. 846 shares vested on January 31, 2025 and 847 shares vested on January 31, 2026.
- F8. Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did QuidelOrtho (QDEL) report for COO Philip McLellan?
How many restricted stock units did the QuidelOrtho (QDEL) COO receive?
What stock options were granted to the QuidelOrtho (QDEL) COO in this Form 4?
How do the new QuidelOrtho (QDEL) RSUs for the COO vest over time?
AI-generated analysis. How Rhea-AI works. Not financial advice.